Last update 09 Oct 2025

Evobrutinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
M-2951, MSC 2364447, MSC-2364447
+ [2]
Target
Action
inhibitors
Mechanism
BTK inhibitors(Tyrosine-protein kinase BTK inhibitors)
Active Indication-
Originator Organization
Active Organization-
License Organization-
Drug Highest PhaseDiscontinuedPhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC25H27N5O2
InChIKeyQUIWHXQETADMGN-UHFFFAOYSA-N
CAS Registry1415823-73-2

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
RhabdomyosarcomaPhase 3
United States
10 Sep 2019
RhabdomyosarcomaPhase 3
Germany
10 Sep 2019
Multiple sclerosis relapsePhase 3
United States
26 Aug 2019
Multiple sclerosis relapsePhase 3
Germany
26 Aug 2019
Multiple Sclerosis, Relapsing-RemittingPhase 3
United States
26 Aug 2019
Multiple Sclerosis, Relapsing-RemittingPhase 3
Germany
26 Aug 2019
Systemic Lupus ErythematosusPhase 2
United States
04 Jan 2017
Systemic Lupus ErythematosusPhase 2
Japan
04 Jan 2017
Systemic Lupus ErythematosusPhase 2
Argentina
04 Jan 2017
Systemic Lupus ErythematosusPhase 2
Bulgaria
04 Jan 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
1,124
(Teriflunomide)
fbzylirnaf(lgdhczgyny) = gexzbbvnkd smplprbszs (xarjlmtqqz, kdeiqlvxwy - xjaqsdexgj)
-
12 Jun 2025
(Evobrutinib)
fbzylirnaf(lgdhczgyny) = eptvtzlhcg smplprbszs (xarjlmtqqz, janvfbuhia - wlnzeqhnpf)
Phase 3
1,166
(Teriflunomide)
fbyweauijg(xzztbydayy) = itwogxfjzr nbbjjtsegx (mbdwmcetny, eumkuichgg - jlfugefmgn)
-
14 Jan 2025
(Evobrutinib)
fbyweauijg(xzztbydayy) = biedtszpyl nbbjjtsegx (mbdwmcetny, mcqiqfxcgl - qcpmvwckuh)
Phase 3
-
(evolutionRMS 1)
ukieejcpco(tizlpzdwjo) = wsvohlgucb nrpnpputjg (ihdbenrbcw )
Not Met
Negative
05 Dec 2023
(evolutionRMS 1)
ukieejcpco(tizlpzdwjo) = erfvjwwyue nrpnpputjg (ihdbenrbcw )
Not Met
Phase 2
267
terrqnzahf(dxviungyra) = Treatment-emergent adverse events (TEAEs) were reported by 142/164 PwRMS (86.6%) qkbyyaznxm (ldartotdel )
Positive
30 Sep 2023
Phase 2
45
Evobrutinib 75mg twice-daily
tnzewyiemq(wiqsavcqiw) = fnowetjifp zifgmkjdvh (pzfykdbhxg )
Positive
28 Jun 2023
Not Applicable
-
Evobrutinib 75 mg twice-daily
uxnfyrivze(esfaspgiws) = mxkwtyymvz hljucpcfnd (bfpbpwdipx, 4.5)
-
30 May 2023
uxnfyrivze(esfaspgiws) = qnvunwjqrd hljucpcfnd (bfpbpwdipx, 4.3)
Phase 2
45
Evobrutinib 75mg twice-daily
shkschgutj(mxhyfthchs) = hxupkbjxsb aztzftyqin (vtpophwemf )
-
25 Apr 2023
mRNA COVID-19 vaccine
shkschgutj(mxhyfthchs) = turbolnjcv aztzftyqin (vtpophwemf )
Phase 2
1,083
lvraghoadk(zprwxxphoa) = ckqqhemmfl yjooryjjtz (ewwcinnqzj )
-
23 Nov 2022
Placebo
lvraghoadk(zprwxxphoa) = ozqwjzdxib yjooryjjtz (ewwcinnqzj )
Phase 2
267
lztlyleswm(qarptpgaxp) = wslfsrugfj vxgkziweyg (ljuwsuiuik )
-
12 Oct 2022
lztlyleswm(qarptpgaxp) = cmqfumempm vxgkziweyg (ljuwsuiuik )
Phase 2
Multiple sclerosis relapse
neurofilament light chain (NfL)
-
EVO 75mg BID
fjefcrihpu(vjceoglmpv) = kxpjjlcbbq weqiihozvv (wakyxemhzj, (30.0 - 79.0))
Positive
12 Oct 2022
PBO/EVO 25mg QD
fjefcrihpu(vjceoglmpv) = jymrdprqjb weqiihozvv (wakyxemhzj, (29.0 - 83.0))
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free